ALK and non-small cell lung carcinoma: A recent phase II trial observed a 47% ORR and a 63% objective intracranial response on 198 ALK-positive, advanced NSCLC sufferers with hypercholesterolemia, hypertriglyceridemia and peripheral neuropathy as prominent AEs [91].